Overview

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) in treatment of Crohn's' disease patient with Certolizumab (Cimzia).
Details
Lead Sponsor:
Baylor College of Medicine
Collaborator:
UCB Pharma
Treatments:
Certolizumab Pegol